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The amino acid leucine is thought to be important for skeletal muscle growth by virtue of its
ability to acutely activate mTORC1 and enhance muscle protein synthesis, yet little data exist
regarding its impact on skeletal muscle size and its ability to produce force. We utilized a tissue
engineering approach in order to test whether supplementing culture medium with leucine
could enhance mTORC1 signaling, myotube growth, and muscle function. Phosphorylation of
themTORC1 target proteins 4EBP-1 and rpS6 andmyotube hypertrophy appeared to occur in a
dose dependent manner, with 5 and 20mM of leucine inducing similar effects, which were
greater than those seen with 1mM. Maximal contractile force was also elevated with leucine
supplementation; however, although this did not appear to be enhancedwith increasing leucine
doses, this effect was completely ablated by co-incubation with the mTOR inhibitor rapamycin,
showing that the augmented force production in the presence of leucine was mTOR sensitive.
Finally, by using electrical stimulation to induce chronic (24 hr) contraction of engineered
skeletal muscle constructs, we were able to show that the effects of leucine and muscle
contraction are additive, since the two stimuli had cumulative effects on maximal contractile
force production. These results extend our current knowledge of the efficacy of leucine as an
anabolic nutritional aid showing for the first time that leucine supplementation may augment
skeletal muscle functional capacity, and furthermore validates the use of engineered skeletal
muscle for highly-controlled investigations into nutritional regulation of muscle physiology.
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1 | INTRODUCTION
Skeletal muscle growth is regulated primarily by the mammalian target
of rapamycin complex 1 (mTORC1) signaling pathway, which enhances
the capacity for mRNA translation and reduces flux through catabolic
pathways such as the autophagy-lysosome and the ubiquitin
proteasome system (Nicklin et al., 2009). mTORC1 signaling has
consistently shown to be activated in response to both muscle loading
(e.g., resistance exercise), and amino acid consumption/treatment
(Marcotte, West, & Baar, 2015), and as such these stimuli represent
excellent candidates as therapies for attenuating the muscle wasting
associated with a number of disease states and ageing. Indeed, acute
human studies have observed activation of mTORC1 and its
downstream targets (e.g., p70S6K, rpS6, and 4EBP-1) following
ingestion of mixed amino acids, and this is coupled with an increase
in muscle protein synthesis (MPS) in the ensuing 60–120min
(Atherton, Etheridge et al., 2010; Koopman et al., 2006; Paddon-
Jones et al., 2004; Volpi, Kobayashi, Sheffield-Moore, Mittendorfer, &
Wolfe, 2003). Furthermore, when human skeletal muscle undergoes
loading prior to amino acid ingestion this effect on mTORC1 signaling
and MPS is potentiated (Moore, Atherton, Rennie, Tarnopolsky, &
Phillips, 2011; Witard et al., 2014). The necessity for mTOR activation
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inmediating theMPS response to both amino acids andmuscle loading
is evidenced by the fact that in rodents, both stimuli fail to augment the
synthetic response when in the presence of the mTOR inhibitor
rapamycin (Anthony et al., 2000; Kubica, Bolster, Farrell, Kimball, &
Jefferson, 2005).
The anabolic properties of amino acid ingestion have been
largely attributed to the essential amino acids, and in particular the
branched chain amino acid leucine. A number of lines of research
support this notion; first, whey protein, which has a high leucine
content results in superior MPS rates in humans compared to soy or
casein, which have lower leucine contents (Tang, Moore, Kujbida,
Tarnopolsky, & Phillips, 2009). Second, ingestion of small quantities
of leucine rich essential amino acids activate the downstream
mTORC1 target p70S6k and MPS in a comparable manner to
20–25 g of whey protein, and to a greater extent than a bolus of
leucine-deficient essential amino acids (Bukhari et al., 2015;
Churchward-Venne et al., 2012), and removal of leucine from an
essential amino acid supplement following muscle loading attenu-
ates mTORC1 signaling (Moberg et al., 2014). Finally, in C2C12
myotubes in vitro, leucine exhibits the most potent stimulation of
mTORC1 signaling compared to all other amino acids (Atherton,
Smith, Etheridge, Rankin, & Rennie, 2010), and its deprivation
impairs protein synthesis and phosphorylation of p70S6k (Talvas,
Obled, Fafournoux, & Mordier, 2006).
In vitro cultures of skeletal muscle provide a controlled and
isolated environment in which to understand cellular and molecular
adaptation, and have improved our understanding of the impor-
tance of amino acids, and in particular leucine, for skeletal muscle
growth (Areta, Hawley, Ye, Chan, & Coffey, 2014; Atherton, Smith
et al., 2010; Talvas et al., 2006). However, a limitation of
conventional in vitro methods is the inability of the rigid
2-dimensional substrate to support muscle contraction, and as
such only acute experiments are typically possible. Tissue
engineered skeletal muscle however allows for skeletal muscle
progenitor cells to be cultured on/inside biologically relevant
substrates in 3-dimensions, and are less stiff, in turn supporting
improvements in levels of skeletal muscle maturation (Engler et al.,
2004), and generation of contractile force. Indeed, the ability to
stimulate and measure contractile force within tissue engineered
skeletal muscle is well reported (Cheng, Davis, Madden, Bursac, &
Truskey, 2014), and while we and others (Martin et al., 2015;
Ostrovidov et al., 2017) have made efforts toward increasing the
biological accuracy of such tissues, the removal of interfacing cell
types (e.g., motor neurons) allows for muscle specific effects of a
given intervention to be explored. As such, engineered skeletal
muscle provides an ideal screening platform in which to better
understand the impact of leucine supplementation on muscle size
and function in an in vitro setting that closely replicates native
skeletal muscle architecture and function.
In the present study, we therefore aimed to determine if
leucine supplementation would enhance contractile force and
myotube size in engineered skeletal muscle, and whether this
phenomenon may be dose-dependent. Furthermore, we sought to
determine the role of the mTOR signaling pathway in regulating
muscle function, and finally aimed to investigate the interaction
between chronic (24 hr) electrical stimulation and leucine supple-
mentation in regulating muscle force. We hypothesized that the
addition of leucine would augment muscle size and force
production in an mTOR dependent manner and that leucine and
electrical stimulation would act together to enhance maximal force
in engineered skeletal muscle.
2 | METHODOLOGY
2.1 | Cell culture
C2C12 myoblasts were purchased from ECACC, and cultured in
growth medium (GM) which consisted of high glucose DMEM
(Sigma–Aldrich, Dorset, UK), 20% FBS (FBS Good: PAN Biotech,
Aidenbach, Germany) and 1% Penicillin-Streptomycin solution
(GIBCO/Fisher Scientific, Leicestershire, UK). GM was replenished
every other day until cells were approximately 80% confluent, at
which point they were trypsinized and counted using the trypan blue
exclusion method prior to plating on fibrin hydrogels. All experi-
ments were conducted using cells which had undergone fewer than
10 passages.
2.2 | Tissue engineered skeletal muscle constructs
Fibrin hydrogels were fabricated as previously described (Martin et al.,
2015). In brief, two 6mm silk sutures were pinned into Sylgard coated
35-mm plates (VWR, Leicestershire, UK) 12mm apart using 0.15mm
minutien pins (Entomoravia, Slavkov u Brna, Czech Republic). Plates
were sterilized by ultraviolet light and washing with 70% ethanol and
left to dry for approximately 3 hr. Each plate then received 500 μl of
GM containing 10U/ml thrombin (Sigma–Aldrich) and 80mg/ml
aprotinin (Sigma–Aldrich) which was spread evenly over the surface
of the plate ensuring the sutures were fully covered. 200 μl of
20mg/ml stock fibrinogen (Sigma–Aldrich) solution was then added to
the plate, and was agitated gently to ensure even distribution and then
left to incubate for 10min at room temperature before being
transferred to the incubator (37°C) for 1 hr. Following polymerization
of the hydrogels, 1 × 105 C2C12 myoblasts were seeded on to the
surface of the gel in 2 ml of GM which contained 0.25mg/ml
6-aminocaproic acid (Sigma–Aldrich) to help prevent degradation of
the fibrin gel. GM was replenished daily for 3 days, at which point the
cells were confluent and the media was switched to differentiation
media (DM) consisting of high glucose DMEM containing 2% Horse
serum (Sigma–Aldrich), 1% Penicillin-streptomycin and 0.5 mg/ml
6-aminocaproic acid. Following 48 hr in DM, media was switched to
maintenance media (MM) in accordance with previous reports
(Khodabukus & Baar, 2009) consisting of high glucose DMEM, 7%
FBS, 1% penicillin- streptomycin, and 0.5mg/ml 6-aminocaproic acid.
MM was changed daily for the duration of the experiment (14 days)
and was supplemented with 1, 5, or 20mM of L-leucine
(Sigma–Aldrich) and/or rapamycin (100 nM; Millipore, Hertfordshire,
UK) from day 9 onward for functional, morphological, and mRNA
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analyses. It is of note that DMEM contains ∼800 μM of L-leucine and
therefore the doses shown throughout represent the supplemented
and not total leucine concentration. For acute mTORC1 signaling
analysis, cultures were maintained in MM until day 14, at which point
leucine was supplemented as described below.
2.3 | Immunoblotting
Following 14 days in culture, MM was removed from the
engineered muscle, which was washed twice in PBS prior to
incubation in Hanks balanced salt solution (HBSS, Sigma–Aldrich)
for 60 min. HBSS was then removed before incubation with HBSS
(Control) or leucine dissolved in HBSS for 30 min, after which
treatment solutions were removed and engineered muscle was
blotted dry, frozen in liquid nitrogen and stored at −80°C until
further analysis. Samples were subsequently homogenized in
200 μl of RIPA lysis buffer (Fisher Scientific) containing a protease
and phosphatase inhibitor cocktail (Fisher Scientific) and rotated
for 1 hr at 4°C before being centrifuged at 12,000 × g in order to
remove insoluble material. The supernatant was transferred to a
fresh tube and protein concentrations were determined using the
Pierce 660 protein assay (Fisher Scientific). Protein was mixed with
4X laemmli buffer (Sigma–Aldrich) and boiled at 95°C for 5 min.
Equal volumes of protein (7.5 μg) were loaded in to precast 4–12%
gradient SDS- polyacrylamide gels (TruPAGE, Sigma–Aldrich) and
separated by electrophoresis at 150V. All samples within a single
experiment were loaded on to a single gel and duplicate gels were
run in order to detect phosphorylated and total proteins. Proteins
were transferred on to nitrocellulose membranes (GE healthcare,
Fisher Scientific) at 0.2A for 90 min, and blocked in 5% BSA at
4°C for 90 min. Thereafter, membranes were washed three times in
tris-buffered saline + 0.1% tween (TBST) and incubated in primary
antibody overnight at 4°C as follows: phospho-4EBP-1 (1:1500),
total-4EBP-1 (1:2000), phospho-rpS6 (1:2000), total-rpS6
(1:2000). All antibodies were purchased from Cell Signaling
Technology, Massachusetts. Following three further washes in
TBST, membranes were incubated for 1 hr at room temperature in
HRP-conjugated anti-rabbit IgG secondary antibody (Sigma–
Aldrich) diluted 1:1500 in TBST containing 5% skimmed milk
powder before detection with chemilluminescence. Imaging and
band quantification were conducted on a ChemiDoc imaging
system (Bio-rad, Hertfordshire, UK) using Quantity One image
software (Version 4.6.8, Bio–rad). Phosphorylation levels are
expressed relative to total protein and α-tubulin (1:2000, Cell
Signaling Technology) abundance, and are presented as a fold
change compared to a single control sample in each experiment.
2.4 | RNA extraction and RT-qPCR
Following 5 days of incubationwith Control, 1 mM, 5mM, or 20mMof
Leucine, engineered muscle constructs were washed once in PBS,
blotted dry, snap frozen in liquid nitrogen and stored at −80°C for
further analysis. Engineeredmuscles were subsequently homogenized
in 500 μl of TRI Reagent (Sigma–Aldrich) and RNA was isolated
according to the manufacturer’s instructions, and re-suspended in
50 μl of RNA storage solution (Fisher Scientific). RNA concentration
and quality was assessed by UV spectroscopy at optical densities of
260 and 280 nm using a Nanodrop 2000 spectrophotometer (Thermo
Fisher, Leicestershire, UK).
RT-qPCR reactions were conducted in triplicate in 384 well plates
and consisted of 20 ng of RNA diluted in 5 μl of nuclease free water,
0.1 μl of both forward and reverse primers at a final concentration of
2 μM (see Tables 1 and S1 for primer sequences), 0.1 μl of Quantifast
reverse transcriptase kit (Qiagen, West Sussex, UK) and 4.7 μl of Sybr
Green mix (Qiagen). One-step RT-qPCR was performed on a Viia7™
thermal cycler (Applied Biosystems/Thermo Fisher), which was
programed to perform the following: 10min at 50°C (reverse
transcription), 5 min at 95°C (“Hot Start” Taq polymerase), followed
by 40 cycles of 95°C for 10 s and 60°C for 30 s. Fluorescence was
detected at the end of each cycle and data were analyzed using the
2(−ΔΔCT
) method (Livak & Schmittgen, 2001) using POLR2B as a
reference gene and a single control construct from each experiment as
a calibrator.
2.5 | Immunostaining
Following 5 days of treatment, each engineered muscle was washed
with PBS and fixed using ice cold methanol; acetone solution.
Subsequently, engineered muscle constructs were cut away from
the sutures and placed on poly-lysine coated microscope slides
(VWR, Leicestershire, UK) and ringed with PAP pen (DAKO,
Cambridgeshire, UK). Constructs were blocked with 1× Tris buffered
saline (TBS; 0.5 M) containing 5% goat serum (Sigma–Aldrich) and
0.2% Triton-x-100 (Fisher Scientific) for 90 min. Following three
washes with TBS, constructs were incubated overnight in a
humidified staining chamber with rabbit polyclonal anti-desmin
primary antibody (Abcam, Cambridgeshire, UK) diluted 1:200 in TBS.
After overnight incubation, constructs were washed three times in
TBS and incubated for 3 hr with goat anti-rabbit TRITC secondary
antibody (Abcam) diluted 1:200 in TBS, and DAPI (Sigma–Aldrich) in
order to visualize nuclei. Following three further washes in distilled
water, constructs were mounted on glass coverslips using a drop of
Fluoromount™ (Sigma–Aldrich) mounting medium. Engineered
muscle constructs were imaged using a Zeiss LSM-710 confocal
microscope (Zeiss, Cambridgeshire, UK) and were analyzed using
Image J software (NIH).
2.6 | Acute functional testing
Functional testing of engineered muscle was conducted as previously
described (Martin et al., 2015). Briefly, at the end of the culture period
(14 days total/5 days of treatment) engineered muscle constructs
were washed twice in PBS and one anchor from the fibrin construct to
be analyzed was removed from the sylgard and attached to a model
403A force transducer (Aurora Scientific, Dublin, Ireland) using
canning wax, and a micro-manipulator was used in order to precisely
control the position of the engineered muscle. Krebs Ringer Hepes
(KRH; 10mM HEPES, 138mM NaCl, 4.7mM KCl, 1.25mM CaCl2,
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1.25mM MgSO, 5mM Glucose, 0.05% Bovine Serum Albumin in
dH2O) buffer solution was added to the dish containing the construct
and two stainless steel electrodeswere placed in position either side of
the construct and submerged in the KRH buffer prior to functional
testing. Impulses were generated using LABview software (National
Instruments, Berkshire, UK) connected to a custom built amplifier and
maximal tetanic contractions were elicited by stimulating at 100Hz at
3.5 V/mm. Data were acquired using a Powerlab 4/25T unit with
associated software (AD instruments, Oxfordshire, UK) with a
sampling rate of 1 KHz.
2.7 | Electrical stimulation
After 13 days in culture, MM was removed from engineered muscle
constructs and constructs were transferred to a custom built 3-D
printed plate and 4ml of respective MM were replenished. A
modified 6-well plate lid with pairs of stainless steel electrodes 1 cm
apart was then placed on to the constructs, with care taken to
ensure that each set of electrodes were positioned either side of the
muscle constructs in order to deliver electric field stimulation.
Electrical stimulation was delivered to the constructs using LABview
software (National Instruments) connected to a custom built
amplifier and in turn attached to the stainless steel electrodes.
Based on a previously published protocol (Khodabukus & Baar,
2012) with some slight modifications, stimulation consisted of 5
bipolar 1 ms pulses delivered at 1 V/mm and 10 Hz with 3.5 s rest
periods. After 24 hr, stimulation was terminated and constructs were
tested as described above in section 2.6.
2.8 | Statistical analysis
All data are presented as mean ± SEM. Normality of distribution and
homogeneity of variance in all data sets were determined using a
Shapiro–Wilk test and Levene’s tests, respectively. Data were
subsequently analyzed using either One–Way ANOVA with Tukey
HSD post–hoc tests or Kruskall Wallis tests where data were not
normally distributed. All analysis was conducted using SPSS version 22.
3 | RESULTS
3.1 | Leucine induces dose-dependent
phosphorylation of downstream mTORC1 targets,
but does not affect proteolytic mRNA expression in
engineered skeletal muscle
Since, acute supplementation with leucine has been shown to activate
mTORC1, initial experiments aimed to see if this effect was also
apparent in engineered muscle, and if it was dose dependent.
Phosphorylation of 4EBP-1Thr37/46, a regulator of cap-dependent
translation appeared to increase in response to leucine, although this
effect did not reach statistical significance (p = 0.07, Figure 1a).
Ribosomal protein S6 (rpS6Ser235/236) phosphorylation, was also
elevated in response to leucine in a dose dependent manner
(0.88 ± 0.12, 1.25 ± 0.11, 1.76 ± 0.33, 1.84 ± 0.24 in control, 1 mM,
5mM, and 20mM groups, respectively; p < 0.05), whereby only
supplementation with 20mM of leucine was sufficient to induce a
statistically significant increase in phosphorylation above control
(Figure 1b).
To determine if leucine had any impact on proteolytic pathways,
mRNA expression of markers of the autophagy-lysosome (Map1lc3a
and Gabarap) and ubiquitin-proteasome (Trim63 and Fbxo32) systems
were measured (Table 2). Five days of leucine supplementation at
increasing doses had no impact on Trim63 (p = 0.88) or Fbxo32
(p = 0.47) mRNA expression, or the levels of Gabarap (p = 0.88) or
Map1lc3a (p = 0.07), although, the latter approached significance
through the observed increase in expression seen with 20mM leucine
supplementation.
3.2 | Leucine supplementation augments myotube
size and contractile force in tissue engineered
skeletal muscle
Leucine had a hypertrophic effect on engineered muscle, as evidenced
by the increase inmyotubewidth in supplementedconstructscompared
with controls. All doses of leucine appeared to result inmyotube growth
TABLE 1 Primer sequences used to investigate proteolytic mRNA expression in the present study
mRNA of interest Primer sequence 5′-3′ Reference number Product length
Trim63 F: CCAAGGAGAATAGCCACCAG NM_001039048.2 84
R: CGCTCTTCTTCTCGTCCAG
Fbxo32 F: CTGAAAGTTCTTGAAGACCAG NM_026346.3 79
R: GTGTGCATAAGGATGTGTAG
Map1lc3a F: AGTTGGTCAAGATCATCCG NM_025735.3 130
R: TCATCCTTCTCCTGTTCATAG
Gabarap F: AATCCGAAAGAAATACCCAG NM_019749.4 175
R: GAAAAACAAGGCATCTTCAG
Polr2b F: GGTCAGAAGGGAACTTGTGGTAT NM_153798.2 197
R: GCATCATTAAATGGAGTAGCGTC
Trim63, Muscle Ring Finger-1; Fbxo32, Muscle Atrophy F-box; Gabarap, Gamma-aminobutyric acid receptor-associated protein; Map1lc3a,
Microtubule-associated protein 1A/1B-light chain 3. Polr2b, RNA polymerase II polypeptide B.
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(Figure 2), with myotube width in constructs supplemented for 5 days
with 1mM leucine measured at 16.3 ± 1.2μm, 5mM at 17.3 ± 2.3μm,
and 20mM at 17.4 ± 1.8μm, compared to control constructs where
myotubewidthwasmeasured at 13.9 ± 1.4μmafter 14days in culture. In
this instance, while the mean increase in myotube width was apparent
compared to controls even with 1mM leucine supplementation, this was
not significant (p = 0.15), and therefore more than 1mM leucine was
required to inducedsignificanthypertrophy inengineeredskeletalmuscle.
C2C12 engineered muscles predominantly expressed type I myosin
heavy chain isoforms and exhibited positive force frequency when
stimulated (Figure S1), thus confirming engineered muscle as a suitable
model of adult skeletal muscle; and thus the effects of leucine on in vitro
muscle functionweredetermined.Theadditionof leucinetothecell culture
media significantly enhanced relative force production (p<0.05), with all
three concentrations associated with elevated tetanic force production
compared to the control constructs (Figure 3). Interestingly, although the
addition of leucine augmented force production, this did not appear to be
dose-dependent,with1, 5, and20mMleucine concentrations augmenting
mean maximal force by 63.5%, 44.5%, and 86.3%, respectively in
comparison to control constructs, with the difference between 5mM
and 20mM reaching statistical significance (p<0.05).
3.3 | Enhanced contractile force with leucine
supplementation is mTOR dependent
To test whether the increase in force associated with leucine
supplementation was mTOR dependent, leucine was next
co-incubated with the mTOR inhibitor rapamycin (see
supplementary Figure S2). We tested engineered skeletal muscle
under five conditions, namely; day 9 control (the time at which
leucine was added), day 14 control, rapamycin alone, leucine
alone, and leucine + rapamycin. Engineered muscle supplemented
with leucine again produced greater contractile force relative to
14 day old control constructs (204.8 ± 9.4 μN vs. 114.8 ± 13.5 μN,
p < 0.05). When leucine was supplemented in combination with
100 nM rapamycin however, the increase in force was completely
blunted. Indeed, the addition of rapamycin either alone
(16.7 ± 1.4 μN) or in combination with leucine (21.6 ± 1.1 μN)
resulted in maximal contractile force lower than that of 14 day
old controls but similar to that of day 9 controls (27.5 ± 1.9 μN,
Figure 4a).
To determine if the blunting of contractile force was driven by
attenuated myotube hypertrophy, engineered muscles were stained
for desmin and myotube widths determined. As expected, co-
incubation of leucine with rapamycin completely blocked hypertro-
phy, with average myotube widths in leucine supplemented
constructs measuring 16.5 ± 3.0 μm compared to 10.5 ± 1.0 μm in
the leucine + rapamycin engineered muscles (p < 0.05), while no
difference existed in myotube width between either day 9 and 14
controls or rapamycin alone or in combination with leucine
(Figure 4b). In addition, there was no difference in the number of
myotubes between conditions (supplementary Figure S2). This
suggests that rapamycin completely attenuates leucine associated
myotube hypertrophy, and furthermore shows that the increase in
contractile force from day 9 to 14 in control constructs is not related
to increased myotube width.
FIGURE 1 Induction of mTORC1 signaling following incubation of tissue engineered skeletal muscle with increasing doses of leucine. (a)
4EBP-1Thr37/47 phosphorylation is increased as the leucine concentration in elevated, although this effect did not reach statistical significance.
(b) rpS6Ser235/236 phosphorylation increased in a dose dependent manner and was only significantly elevated above control with the addition
of 20mM of leucine. Data are mean ± SEM for a minimum of n = 4 engineered muscles. * indicates statistically greater than control (p < 0.05)
TABLE 2 Proteolytic mRNA expression following 5 days of incubation of tissue engineered skeletal muscle with increasing doses of leucine
Control 1 mM Leu 5mM Leu 20mM Leu p-value
Trim63 0.94 ± 0.11 0.87 ± 0.13 0.90 ± 0.12 0.93 ± 0.14 0.81
Fbxo32 1.10 ± 0.07 1.19 ± 0.06 1.07 ± 0.03 1.10 ± 0.05 0.47
Map1lc3a 1.22 ± 0.18 1.11 ± 0.02 1.09 ± 0.07 1.60 ± 0.28 0.07
Gabarap 1.07 ± 0.06 1.08 ± 0.03 1.05 ± 0.01 1.09 ± 0.04 0.88
Data are expressed as mean ± SEM for n = 4 engineered muscles.
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3.4 | Leucine in combination with contractile activity
cumulatively improve muscle function
Since, both muscle loading and amino acids have the capability to
enhancemuscle size in vivo, it was next askedwhether a combination of
leucine supplementation andmuscle contraction canadditively increase
muscle function in vitro. Maximal contractile force was significantly
enhanced by leucine supplementation (383.8 ± 27.6 μN), electrical
stimulation (392.6 ± 38.5 μN) and a combination of leucine and
electrical stimulation (502.4 ± 69.3 μN) compared to control engineered
skeletal muscle (240.8 ± 8.7 μN, p < 0.05). Moreover, while the effects
of leucine (59.4% increase) and electrical stimulation (63.0% increase)
augmented force to a similar extent), the effects of the two stimuli in
combination resulted in maximal contractile force higher than either
stimulus in isolation (108.6% increase, Figure 5a), although this did not
reach statistical significance (leucine vs. leucine + Stimulation, p = 0.06).
Interestingly, subsequent immunocytochemical analysis revealed
that myotubewidthwas increased in response to electrical stimulation
(13.3 ± 0.7 μm), leucine (14.7 ± 0.6 μm) and stimulation plus leucine in
combination (15.4 ± 0.9 μm) compared to control (10.6 ± 0.2 μm,
p < 0.05). Myotube width was significantly greater in leucine
supplemented engineered constructs and leucine plus electrical
stimulation constructs compared to electrical stimulation alone
(p < 0.05), however no difference was apparent between leucine
alone and in combination with electrical stimulation (p = 0.484,
Figure 5b).
4 | DISCUSSION
Ingestion of amino acids and particularly the branched chain amino
acid leucine has been shown to be capable of activating acute anabolic
intracellular signaling and MPS (Apro et al., 2015; Churchward-Venne
et al., 2012; Moberg et al., 2014), however there are little data which
have examined the more chronic effects of leucine on skeletal muscle
FIGURE 3 Leucine supplementation increases contractile force in engineered skeletal muscle independent of dose. Maximal contractile
force was enhanced in engineered constructs supplemented with leucine for 5 days at the end of the culture period. Data are expressed as
mean ± SEM for n = 5 engineered muscles. * indicates statistically greater than control (p < 0.05), # indicates statistically greater than 5mM
(p < 0.05)
FIGURE 2 Myotube hypertrophy following 5 days of supplementation of engineered skeletal muscle with increasing doses of leucine.
Desmin staining (red) of myotubes was significantly (p < 0.05) increased with 5 and 20mM of leucine supplementation. Myotubes are
counterstained with DAPI (blue) and scale bar indicates 50 µm. Data are expressed as mean ± SEM for n = 5 engineered muscles. * indicates
statistically greater than control (p < 0.05)
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mass and function, largely due the lack of appropriately controlled
experimental model. In the present study, we used tissue engineered
skeletal muscle to determine if leucine could enhance contractile
function and drive muscle hypertrophy in vitro. Our data suggest that
leucine activates mTORC1 signaling, and augments muscle size and
function in engineered muscle and that this improvement in maximal
force production is mTOR sensitive. We also found that both leucine
and chronic muscle contraction are capable of increasingmuscle force,
and together result in greater functional enhancement than either
stimulus in isolation.
It is well recognized that mTORC1 activation leads to elevations in
translation initiation and ribosome biogenesis, in turn enhancing MPS
and capacity for cellular growth. We show here in engineered skeletal
muscle, that leucine activates the downstream effectors of mTORC1,
namely 4EBP-1 and rpS6, confirming previous studies conducted both
in conventional in vitro culture and in vivo (Anthony et al., 2000;
Areta et al., 2014; Atherton, Smith et al., 2010; Churchward-Venne
et al., 2012), and thus providing strong validation for the use of
engineeredmuscle for investigations in this area. Interestingly, we also
found that this effect on mTORC1 signaling appears to be dose
dependent, with higher doses (5–20mM) required in order to
maximize the response. This is somewhat in agreement with Areta
et al. (2014) who found a dose dependent increase in p70S6 kinase
phosphorylation with leucine supplementation, although, this was not
mirrored in other mTORC1 related protein kinases tested. Further-
more, in the present study we found that 5 days of leucine
supplementation had no effect on the expression of markers of the
ubiquitin-proteasome or autophagy-lysosome system. This was
slightly surprising since mTORC1 activation is associated with
inhibition of autophagy (Sandri, 2013), and there is evidence that
amino acid ingestion can also prevent elevations in MuRF-1 (Trim63)
and MAFbx (Fbxo32) expression at rest and following exercise
FIGURE 5 Combination effects of leucine and electrical
stimulation on engineered skeletal muscle function and myotube
size. (a) Leucine and electrical stimulation augment maximal force
production independently, and in combination further increase force
production above control. (b) myotube growth is enhanced by both
electrical stimulation and leucine above control, while leucine
appears to have the greater effect on myotube size overall. Data
are mean ± SEM from a minimum of n = 4 engineered muscles.
* indicates statistically greater than control (p < 0.05), # indicates
statistically greater than stimulation alone (p < 0.05)
FIGURE 4 Leucine associated increases in contractile force and
myotube size are mTOR dependent. (a) Addition of the mTOR
inhibitor rapamycin (100 nM) for the final 5 days of culture either
alone or in combination with leucine (20mM) resulted in blunted
maximal force production which was similar to that seen at day 9 of
culture and lower than that observed after 14 days of culture. (b)
Rapamycin prevented the leucine induced myotube hypertrophy,
but did not induce significant atrophy of the myotubes. Data are
mean ± SEM for a minimum of n = 4 engineered muscles. * indicates
statistically greater than 9 day Control (p < 0.05), # indicates
significantly greater than 14 day control (p < 0.05)
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(Borgenvik, Apro, & Blomstrand, 2012; Herningtyas et al., 2008). Our
in vitro data support in vivo human data reporting no alterations in
proteolytic gene expression following ingestion of leucine or its
metabolite β-Hydroxy-β-methylbutyrate in healthy young men
(Wilkinson et al., 2013), although, since we measured changes in
mRNA expression, we cannot discount the possibility that differences
may have been observed at an earlier time point.
Myotube growth following chronic leucine supplementation
followed a similar dose-dependent trend to that of the mTORC1
signaling induction. Indeed, although myotube hypertrophy was
observed with 1mM leucine supplementation, this effect was not
statistically significant until higher doses were supplemented.
Furthermore, this concordance between the anabolic signaling
response and the alteration in myotube hypertrophy supports the
work of (Mitchell et al., 2014), which showed a positive relationship
between 4EBP-1 phosphorylation and changes in muscle volume with
resistance training in men, suggesting that the responses observed in
vivo are closely mirrored in engineered skeletal muscle in vitro.
A key finding of our study was that supplementing the culture
media of engineered skeletal muscle constructs with leucine for the
final 5 days of experimentation augmented maximal contractile force
by up to ∼80%. Indeed, while other investigations have observed an
augmented functionality of engineered muscles following chronic
treatment with pharmacological agents (Madden, Juhas, Kraus,
Truskey, & Bursac, 2015; Syverud, VanDusen, & Larkin, 2016; Weist
et al., 2013), this represents the first report of how amino acids can
enhance skeletal muscle contractile function in vitro, thus providing
novel data regarding leucine’s anabolic properties. Furthermore, the
present data show that the enhancement in maximal force production
in the presence of leucine was not dose-dependent, which is in
contrast to our findings for signaling through mTORC1 and myotube
size, and perhaps suggests that the additional muscle growth at higher
leucine doses is partially a result of accretion of non-contractile
proteins.
Rapamycin completely blunted the increase in force which was
found to occur over the final 5 days of culture (day 9–14) in the
absence of leucine, suggesting that this adaptation is mTOR
dependent. Moreover, since neither myotube size or total number
were reduced with rapamycin treatment, and were not different over
the final 5 days of culture, the increase in force is likely due to other
mTOR dependent processes leading to maturation of the myotubes.
Indeed, in mice where mTOR is specifically knocked out in skeletal
muscle maximal force production was reduced even when accounting
for the loss of muscle size, and this force decrement was associated
with reduced expression of components of the dystrophin-dystrogly-
can complex (Risson et al., 2009). While this was not a primary
outcome of the present study, it would be interesting in the future to
determine the reasons for blunted force production in engineered
skeletal muscle treated with rapamycin.
When rapamycin was incubated alongside leucine the measured
contractile force was equivalent to that measured at 9 days of culture
(i.e., less than that observed at day 14 in the absence of leucine), clearly
showing that leucine augments contractile force in an mTOR sensitive
manner.Rapamycinalsocompletelyblunted leucineassociatedmyotube
growth, similar to previous findings in rodents following compensatory
hypertrophy (Bodine et al., 2001), suggesting that the impact on muscle
force was at least partially due to lack of muscle growth.
Since, muscle loading (e.g., resistance exercise) and amino acids
can stimulate mTORC1 and protein synthesis through diverse
mechanisms (Marcotte et al., 2015), and as such implement an
additive effect on muscle growth, we conducted a final set of
experiments to determine if this effect could be modelled in vitro, and
whether the two stimuli would act together to increase maximal
muscle force production. It was found that both leucine and electrical
stimulation alone resulted in an approximately 60% increase in
maximal force production, while combining the two stimuli resulted in
an approximately 110% increase in contractile force compared to
control muscles. The augmentation of maximal contractile force of
engineered skeletal muscle described here is pertinent for the tissue
engineering community, since a considerable limitation in the use of
engineeredmuscle constructs for regenerativemedicine lies in the fact
that force production is far less than that of native muscle (Bian &
Bursac, 2008). As such, the present data reveals that the use of
electrical stimulation in combination with leucine may help to
overcome this limitation, and when used in combination with other
factors such as TGF-β or agrin, which have previously been shown to
enhance contractile force (Bian & Bursac, 2012; Weist et al., 2013)
may allow the use of engineered muscle for regenerative medicine to
become a reality.
While electrical stimulation alone also resulted in myotube
hypertrophy, in our system, and with the variables tested, leucine
appears to be a greater driver of muscle growth since leucine alone
resulted in greater hypertrophy than stimulation alone and was not
different to leucine and stimulation in combination. This may be a
result of the discrepancy between respective intervention times (i.e.,
24 hr stimulation vs. 5 days leucine), and it is of note that the
stimulation regime was chosen based on a protocol known to enhance
contractile force. Khodabukus & Baar (2012) have previously
established that the augmentation in force as a consequence of the
same 24 hr electrical stimulation as used in the present study can only
be ablated by approximately 40% in the presence of rapamycin,
suggesting that the additional increase in force is driven through
alternative mechanisms and not myotube hypertrophy. In the future it
would be interesting to see if longer periods of contractile activity
result in increased myotube growth, and whether the effect of leucine
remains additive.
In conclusion, the present work shows that the amino acid leucine
can activatemTORC1 signaling andmuscle growth in tissue engineered
skeletal muscle and that this response appears to be somewhat dose
dependent. Importantly, we show for the first time that leucine can
enhance maximal contractile force in an mTOR-sensitive manner and
that leucine and electrical stimulation can be used together to augment
this response. These data provide strong validation for the use of
engineered skeletal muscle as a tool in biomedical research concerned
with nutrition and skeletal muscle physiology and function, and
highlights the potential for leucine supplementation as a clinical
therapy in conditions associated with impaired muscle strength and
reduced size.
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